Piezo Motion Announces Expansion of Its Precision Motion Motors with New Partnership
Piezo Motion joins forces with Electroline Sales, Inc. to offer disruptive motion control technology to Electroline Sales, Inc.’s diverse customer base
LAKEWOOD RANCH, Fla., Feb. 17, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Piezo Motion, a Brain Scientific (OTCQB:BRSF) company, and Electroline Sales, Inc. today announce a partnership. Piezo Motion is a developer and leading manufacturer of automation technology. Electroline Sales, Inc., based in Edina, Minnesota, is a manufacturing representative serving many original equipment manufacturers (OEMs) in the Upper Midwest.
Piezo Motion’s unique motion control technology will enable Electroline Sales, Inc. to provide precision motor solutions at an affordable price to companies that specialize in medical, agricultural, defense, robotics, automation, 3D printers and lab equipment. Electroline Sales, Inc. serves Minnesota, Iowa, Wisconsin, South Dakota, North Dakota and northern Illinois. Piezo Motion’s multifaceted rotary and linear motors are built with technology that provides a stable, accurate motor designed specifically for OEMs that require ultimate speed, size and accuracy.
“We are pleased to start this new partnership with Piezo Motion,” said Tim Smith, president and owner of Electroline Sales, Inc. “At Electroline Sales, we pride ourselves on continually offering our customers and potential customers new ideas and technologies that will ultimately improve their product offering. The motors and linear actuators produced by Piezo Motion are components that should be of great interest to many of the companies in our territory.”
Piezo Motion motors are used globally for a variety of applications. These include laboratory instruments, biomedicine, optics, semiconductors, nanotechnology industries, and industrial electronic and automotive systems, along with an expanding portfolio of products that combine performance with dramatically lower cost over conventional piezo solutions.
“We have seen a surge in demand from devices manufacturers looking for more precision than what is currently available,” said Hassan Kotob, chairman and CEO of Brain Scientific. “The partnership with Electroline Sales will allow our innovative and affordable rotary and linear motors to integrate into new product designs that require unparalleled accuracy and precision.”
About Piezo Motion
Piezo Motion (piezomotion.com), a Brain Scientific company, is a leader in precision motor technology with multimillion-dollar investments in research and development of affordable piezoelectric motors to meet, and exceed, the needs of today's global markets. The company is committed to the development of innovative technology and motion products that enhance functionality in a multitude of applications. The company works with startups, OEMs, research institutions and industrial companies from around the world, empowering the visionaries behind their products.
About Brain Scientific
Brain Scientific (brainscientific.com) is a medical technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of neurodiagnostic and OEM medical devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap and NeuroEEG are smart neurological diagnostic devices that simplify administration, shorten scan time and cut costs. The Piezo Motion product line consists of ultraefficient compact precision motors that will drive the next generation of medical devices. To learn more about Brain Scientific's corporate strategy, products or investor relations, please visit brainscientific.com.
About Electroline Sales, Inc.
Electroline Sales, Inc. (electrolinesales.com) is a skilled manufacturer’s representative serving a wide variety of OEMs in the Upper Midwest. For more than 20 years, the company has worked hand in hand with its customers to integrate a vast selection of motors and other related motion control components into new product designs. Electroline Sales, Inc. works with companies specializing in medical, agricultural, off-road vehicle, defense, robotics, automation, 3D printers and lab equipment. Electroline Sales, Inc. covers the states of Minnesota, Iowa, Wisconsin, South Dakota, North Dakota and Northern Illinois.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company's future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company's inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company's inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company's raw materials; and the failure to implement the company's business plans or strategies. Some of these and other factors are identified and described in more detail in the company's filings with the SEC. The company does not undertake to update these forward-looking statements.
Released February 17, 2022